Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Front-line and R/R updates in CLL from EHA

Peter Hillmen • 17 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Antibodies Chlorambucil Ibrutinib Obinutuzumab Venetoclax Zanubrutinib
CAPTIVATE CLARITY CLL14

Peter Hillmen, MBChB, FRCP, FRCPath, PhD, of the University of Leeds, Leeds, UK, explores highlights in frontline chronic lymphocytic leukemia (CLL) treatment from EHA 2020, including venetoclax and obinutuzumab combinations from the CLL14 trial (NCT02242942), as well as Phase II results investigating triplet ibrutinib, obinutuzumab and venetoclax treatment. Dr Hillmen also discusses data evaluating acalabrutinib in the relapsed/refractory (R/R) setting as well as results from the CLARITY and CAPTIVATE (NCT02910583) trials. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Peter Hillmen

1:55
Key updates from the interim analysis of the FLAIR trial
Peter Hillmen • 10 Jun 2022
1:03
CLL trial updates from EHA 2022
Peter Hillmen • 10 Jun 2022
1:19
Acalabrutinib vs ibrutinib in previously untreated high-risk CLL
Peter Hillmen • 10 Jun 2022
1:40
The role of MRD in decision-making in CLL
Peter Hillmen • 10 Jun 2022

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals